Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparan sulfate 6-mer is a synthetic, structurally homogeneous hexasaccharide (oligosaccharide) produced through chemoenzymatic synthesis. It is primarily utilized as a research compound to investigate the anti-inflammatory and anticoagulant properties of heparan sulfate in a controlled, chemically defined manner. Preclinical studies have demonstrated its potential in protecting against sepsis and liver ischemia-reperfusion injury by neutralizing pro-inflammatory mediators such as extracellular histones (e.g., Histone H3) and high mobility group box 1 (HMGB1). While it shares some biological activities with longer heparan sulfate oligosaccharides like the 12-mer and 18-mer, the 6-mer represents a smaller structural unit often used to define the minimal binding motifs required for therapeutic efficacy. No commercial developer or clinical trials have been identified for this specific compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparan sulfate 6-mer.